The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.
Susan Haigney
Advertisement
Susan Haigney is lead editor of Pharmaceutical Technology and Pharmaceutical Technology Europe.
Articles by Susan Haigney
CDMOs and CMOs will continue to invest in biopharmaceutical services and facilities as the bio/pharmaceutical industry looks to biosimilars and personalized medicine.
Advertisement
Latest Updated Articles
- Growth in Biologics Market Inspires Outsourcing
Published: February 1st 2020 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
5
